EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access · CC BY 4.0

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

Audrey Fresse iD, Christophe Hommel, Nadine Petitpain, Philippe Kerschen

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70490 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Audrey Fresse und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regional Pharmacovigilance Center of Nancy, Pharmaco-toxicology Department, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colitis. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature.

Methods

To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and disproportionality analysis of ocrelizumab‐induced colitis registered in VigiBase, as well as an extensive literature review and a description of two cases from Luxembourg reported to our pharmacovigilance centre.

Results

Our VigiBase analysis revealed 400 cases of ocrelizumab‐induced colitis, with 79.0% serious cases and a median time to onset of 17 months. The preferred term (PT) coded was ‘colitis’ (53.0%), followed by PTs related to inflammatory bowel diseases (33.5%). Significant disproportionality was found for high‐level term ‘colitis’ and for ‘colitis’, ‘colitis microscopic’ and ‘immune‐mediated enterocolitis’ PTs. Our literature review revealed 24 case reports corresponding to 36 patients with a median time to onset of 18 months and a predominance of unspecified colitis (61.1%) and inflammatory bowel diseases (27.8%). Two patients relapsed after ocrelizumab resumption.

Conclusions

Together, our findings of two relevant clinical cases of ocrelizumab‐induced colitis, the literature review and the significant VigiBase disproportionality, suggest a potential safety signal for ocrelizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedColitisFemaleHumansMaleMiddle AgedAdverse Drug Reaction Reporting SystemsMultiple SclerosisPharmacovigilance

Stichwörter der Autor:innen

adverse drug reactioncolitisdisproportionality analysisocrelizumabpharmacovigilance

Substanzen

Antibodies, Monoclonal, Humanizedocrelizumab

Autor:innen und Institutionen

  • Regional Pharmacovigilance Center of Nancy, Pharmaco-toxicology Department, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France.
  • Department of Gastroenterology, Centre Hospitalier Emile Mayrisch, Esch sur Alzette, Luxembourg.
  • Department of Neurology, Centre Hospitalier Luxembourg, Luxembourg-Ville, Luxembourg.

ORCID-Profile: Audrey Fresse

Zitieren

APA

Fresse, A., Hommel, C., Petitpain, N., & Kerschen, P. (2026). Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70490

Vancouver

Fresse A, Hommel C, Petitpain N, Kerschen P. Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70490

BibTeX
@article{Fresse2026,
  author = {Fresse, Audrey and Hommel, Christophe and Petitpain, Nadine and Kerschen, Philippe},
  title = {Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70490}
}
Kostenlos starten →